- The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
- Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, Foulkes WD, Neuhausen SL, Senter L, Moller P, Bordeleau L, Fruscio R, Velsher L, Zakalik D, Olopade OI, Eng C, Pal T, Cullinane CA, Couch FJ, Kotsopoulos J, Sun P, Lubinski J, Narod SA.
- Cancer. 2022 Dec 26. doi: 10.1002/cncr.34615. Epub ahead of print.
- PMID: 36571512
- PubMed abstract
- Source abstract
- Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
- Vertechy L, Boccia SM, Tiberi G, Avesani G, Corrado G, Fagotti A, Scambia G, Marchetti C.
- Int J Gynecol Cancer. 2022 Dec 23:ijgc-2022-003764. doi: 10.1136/ijgc-2022-003764. Epub ahead of print.
- PMID: 36564097
- PubMed abstract
- Source abstract
- Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
- Jackson LM, Moldovan GL.
- NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.
- PMID: 36568963
- PubMed abstract
- Review
- Free PMC article
- Free Full Text
- Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment.
- Wang C, Gao P, Xu J, Liu S, Tian W, Liu J, Zhou L.
- Front Pharmacol. 2022 Dec 7;13:1078303. doi: 10.3389/fphar.2022.1078303.
- PMID: 36569329
- PubMed abstract
- Review
- Free PMC article
- Free Full Text
- December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad.
- Matulonis U, O'Malley D.
- Gynecol Oncol. Podcasts. 2022 Dec.
- Podcast
- Podcasts
- Free audio
•• Original research:
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
- PMID: 36273926
- PubMed abstract
- Source abstract
- Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
- Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL.
- Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.11.003. Epub ahead of print.
- PMID: 36564284
- PubMed abstract